Elanco Animal Health (NYSE:ELAN) Given New $17.00 Price Target at UBS Group

Elanco Animal Health (NYSE:ELAN) had its price objective lowered by UBS Group from $18.00 to $17.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also issued reports about the company. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Morgan Stanley cut their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday. Stifel Nicolaus decreased their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Barclays dropped their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Leerink Partners initiated coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $15.57.

Elanco Animal Health Stock Up 4.2 %

NYSE ELAN opened at $11.15 on Wednesday. Elanco Animal Health has a 1 year low of $10.20 and a 1 year high of $18.80. The stock has a market capitalization of $5.51 billion, a PE ratio of 27.88, a PEG ratio of 2.50 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The business’s 50-day moving average is $11.74 and its 200 day moving average is $13.06.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the prior year, the business posted $0.08 earnings per share. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. Sell-side analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

A number of large investors have recently added to or reduced their stakes in the stock. CoreCap Advisors LLC purchased a new position in shares of Elanco Animal Health in the 4th quarter worth $29,000. AM Squared Ltd bought a new position in Elanco Animal Health in the third quarter valued at about $34,000. Wilmington Savings Fund Society FSB purchased a new position in Elanco Animal Health in the third quarter worth about $35,000. Farther Finance Advisors LLC grew its stake in shares of Elanco Animal Health by 158.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after purchasing an additional 2,044 shares during the period. Finally, Venturi Wealth Management LLC increased its position in shares of Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after purchasing an additional 1,601 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.